[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …
J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - ncbi.nlm.nih.gov
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be
effective in patients with brain metastases. However, direct comparative studies of the
pharmacokinetics and efficacy of these three drugs in treating brain metastases are lacking.
In the present investigation, we found that gefitinib penetrated the blood-tumor barrier and
was distributed to brain metastases more effectively than erlotinib or icotinib in a nude …
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be
effective in patients with brain metastases. However, direct comparative studies of the
pharmacokinetics and efficacy of these three drugs in treating brain metastases are lacking.
In the present investigation, we found that gefitinib penetrated the blood-tumor barrier and
was distributed to brain metastases more effectively than erlotinib or icotinib in a nude …
以上显示的是最相近的搜索结果。 查看全部搜索结果